vs
Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and Fulgent Genetics, Inc. (FLGT). Click either name above to swap in a different company.
Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $83.3M, roughly 1.0× Fulgent Genetics, Inc.). On growth, Amalgamated Financial Corp. posted the faster year-over-year revenue change (9.4% vs 9.3%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-83.1M). Over the past eight quarters, Fulgent Genetics, Inc.'s revenue compounded faster (13.7% CAGR vs 4.3%).
CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.
Fulgent Genetics, Inc. is a molecular diagnostics technology firm that develops and offers genetic testing services including carrier screening, oncology testing, infectious disease detection, and hereditary condition analysis, serving clinical providers, pharma firms, research institutions and public health groups primarily in North America.
AMAL vs FLGT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.2M | $83.3M |
| Net Profit | — | $-23.4M |
| Gross Margin | — | 39.1% |
| Operating Margin | 39.0% | -43.5% |
| Net Margin | — | -28.1% |
| Revenue YoY | 9.4% | 9.3% |
| Net Profit YoY | — | -297.7% |
| EPS (diluted) | $0.88 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.2M | $83.3M | ||
| Q3 25 | $85.6M | $84.1M | ||
| Q2 25 | $80.9M | $81.8M | ||
| Q1 25 | $77.0M | $73.5M | ||
| Q4 24 | $77.9M | $76.2M | ||
| Q3 24 | $81.0M | $71.7M | ||
| Q2 24 | $78.5M | $71.0M | ||
| Q1 24 | $78.3M | $64.5M |
| Q4 25 | — | $-23.4M | ||
| Q3 25 | $26.8M | $-6.6M | ||
| Q2 25 | $26.0M | $-19.0M | ||
| Q1 25 | $25.0M | $-11.5M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $27.9M | $-14.6M | ||
| Q2 24 | $26.8M | $-8.7M | ||
| Q1 24 | $27.2M | $-13.5M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 42.2% | ||
| Q2 25 | — | 42.1% | ||
| Q1 25 | — | 38.6% | ||
| Q4 24 | — | 41.8% | ||
| Q3 24 | — | 37.3% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 34.3% |
| Q4 25 | 39.0% | -43.5% | ||
| Q3 25 | 42.9% | -18.3% | ||
| Q2 25 | 43.8% | -24.1% | ||
| Q1 25 | 45.1% | -26.9% | ||
| Q4 24 | 42.4% | -21.2% | ||
| Q3 24 | 47.2% | -23.8% | ||
| Q2 24 | 45.6% | -26.6% | ||
| Q1 24 | 49.2% | -33.8% |
| Q4 25 | — | -28.1% | ||
| Q3 25 | 31.3% | -7.9% | ||
| Q2 25 | 32.1% | -23.2% | ||
| Q1 25 | 32.5% | -15.7% | ||
| Q4 24 | — | -7.7% | ||
| Q3 24 | 34.5% | -20.4% | ||
| Q2 24 | 34.1% | -12.3% | ||
| Q1 24 | 34.8% | -20.9% |
| Q4 25 | $0.88 | — | ||
| Q3 25 | $0.88 | — | ||
| Q2 25 | $0.84 | — | ||
| Q1 25 | $0.81 | — | ||
| Q4 24 | $0.78 | — | ||
| Q3 24 | $0.90 | — | ||
| Q2 24 | $0.87 | — | ||
| Q1 24 | $0.89 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $291.2M | $50.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $794.5M | $1.1B |
| Total Assets | $8.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $291.2M | $50.2M | ||
| Q3 25 | $115.5M | $117.6M | ||
| Q2 25 | $171.1M | $87.9M | ||
| Q1 25 | $65.7M | $67.3M | ||
| Q4 24 | $60.7M | $55.1M | ||
| Q3 24 | $149.2M | $58.0M | ||
| Q2 24 | $58.0M | $65.1M | ||
| Q1 24 | $155.2M | $54.7M |
| Q4 25 | $794.5M | $1.1B | ||
| Q3 25 | $775.6M | $1.1B | ||
| Q2 25 | $754.0M | $1.1B | ||
| Q1 25 | $736.0M | $1.1B | ||
| Q4 24 | $707.7M | $1.1B | ||
| Q3 24 | $698.2M | $1.1B | ||
| Q2 24 | $646.0M | $1.1B | ||
| Q1 24 | $616.8M | $1.1B |
| Q4 25 | $8.9B | $1.2B | ||
| Q3 25 | $8.7B | $1.2B | ||
| Q2 25 | $8.6B | $1.2B | ||
| Q1 25 | $8.3B | $1.2B | ||
| Q4 24 | $8.3B | $1.2B | ||
| Q3 24 | $8.4B | $1.2B | ||
| Q2 24 | $8.3B | $1.2B | ||
| Q1 24 | $8.1B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $135.8M | $-78.1M |
| Free Cash FlowOCF − Capex | $134.4M | $-83.1M |
| FCF MarginFCF / Revenue | 157.8% | -99.7% |
| Capex IntensityCapex / Revenue | 1.6% | 6.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $229.4M | $-124.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $135.8M | $-78.1M | ||
| Q3 25 | $39.5M | $11.1M | ||
| Q2 25 | $24.9M | $-30.2M | ||
| Q1 25 | $34.2M | $-4.4M | ||
| Q4 24 | $124.1M | $25.0M | ||
| Q3 24 | $35.8M | $-15.5M | ||
| Q2 24 | $28.0M | $4.3M | ||
| Q1 24 | $31.3M | $7.3M |
| Q4 25 | $134.4M | $-83.1M | ||
| Q3 25 | $38.3M | $5.1M | ||
| Q2 25 | $24.2M | $-37.0M | ||
| Q1 25 | $32.5M | $-9.1M | ||
| Q4 24 | $122.3M | $21.2M | ||
| Q3 24 | $35.2M | $-35.0M | ||
| Q2 24 | $27.8M | $-8.7M | ||
| Q1 24 | $31.1M | $3.2M |
| Q4 25 | 157.8% | -99.7% | ||
| Q3 25 | 44.7% | 6.0% | ||
| Q2 25 | 29.9% | -45.2% | ||
| Q1 25 | 42.2% | -12.5% | ||
| Q4 24 | 157.0% | 27.9% | ||
| Q3 24 | 43.4% | -48.8% | ||
| Q2 24 | 35.4% | -12.2% | ||
| Q1 24 | 39.7% | 5.0% |
| Q4 25 | 1.6% | 6.0% | ||
| Q3 25 | 1.4% | 7.2% | ||
| Q2 25 | 0.9% | 8.3% | ||
| Q1 25 | 2.3% | 6.4% | ||
| Q4 24 | 2.3% | 5.0% | ||
| Q3 24 | 0.7% | 27.2% | ||
| Q2 24 | 0.3% | 18.2% | ||
| Q1 24 | 0.3% | 6.3% |
| Q4 25 | — | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMAL
Segment breakdown not available.
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
